TRISCEND II Pivotal Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 864 participants.

Also called NCT04482062

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 864 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04482062
Other papers using this trial's data
  • TRISCEND II: Effect of Transcatheter Tricuspid Valve Replacement on Echocardiographic Measures of Right Heart Remodeling and Function JACC. Cardiovascular imaging, 2026-09 DOI, PubMed 42470411

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Germany (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04482062. Randomized; no masking; primary purpose treatment. Start 2021-04-09 (actual); primary completion 2025-12-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TRISCEND II Pivotal Trial
Condition
Tricuspid Valve Regurgitation
Condition
Tricuspid Valve Insufficiency
Condition
Tricuspid Valve Disease
Condition
Heart Valve Diseases
Condition
Cardiovascular Diseases
Condition
Heart Failure
Intervention (Device)
Edwards EVOQUE System
Intervention (Drug)
Optimal Medical Therapy
Lead sponsor
Edwards Lifesciences (class: industry)

Record details

Record id
cardio:ct-nct04482062
Content hash
bd653d362f11d1230851bcc09057d5194df114a0da71b8294a7f29cfcfcf0279